While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

Cardiff Oncology, Inc. (CRDF) is developing novel therapeutic candidates to treat various types of cancer, with an initial focus on RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC) indications.Cardiff’s pipeline only comprises its lead investigational candidate, onvansertib, which is currently being evaluated in combination with standard-of-care (SOC) therapeutics in separate early to mid-stage studies to treat mCRC and mPDAC.Onvansertib is an oral and ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Cardiff Oncology (CRDF) shares soared 20.5% in the last trading session to close at $5.40. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 169.9% gain over the past four weeks.The sudden rise in the stock price can be attributed to the positive investor mindset regarding the company's pipeline, which comprises only its lead candidate, onvansertib. Cardiff Oncology oncology is currently developing onvansertib in separate early to ...

Vladimir Vladimirov/E+ via Getty Images Topline Summary and Update Cardiff Oncology (NASDAQ:CRDF) is a cancer-focused biotech working on developing a drug that exploits a novel target, particularly in colorectal cancer. In my past articles, I have been lukewarm to slightly pessimistic about their findings presented to date and their overall outlook. But recent news has sent them on a meteoric rise, and the ensuing roller coaster has readers asking me directly for input on this company. So let's examine ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.23%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.29 per share when it actually produced a loss of $0.22, delivering a surprise of 24.14%.Over the last four quarters, th ...

Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Laurence Watts - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Fairooz Kabbinavar - Chief Medical Officer Jamie Levine - Chief Financial Officer Conference Call Participants Mark Frahm - TD Cowen Joseph Catanzaro - Piper Sandler Andy Hsieh - William Blair Operator Welcome to the Cardiff Oncology Fourth Quarter and Full-Year 2023 Financial Results and Corporate ...

F Runway with current cash extends into 3Q 2025 Bev Naïve d all adverse or all adverse events entered into the EDC as of January 3, 2024, from an organing trial and unboked dratabase. N. number of potients revents shown occurred i the event, (regardless of causalitiy) each politient it a only counted once and only for the highest grade of a given event. TEAEs: Treatment Emergent Adverse Events; Gounm 33 Annual eligible US patients* In CRDF-004, each arm will have an equal number of FOLFIRI/bev and FOLFOX/be ...

- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data from first-line RAS-mutated mCRC trial is expected in mid-2024 - - New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Cash and equivalents of $75 million as of December 31, ...